B9

Quantitative Analysis of IL-6 Binding and Bioactivity in B9 Cells

Despite the clinical importance of cytokines like IL-6, the quantitative relationship between molecular binding and cellular activation thresholds remains unclear. Utilizing validated tools such as iodinated IL-6 and B9 hybridoma bioassays, Hansen et al. employed equilibrium binding principles and experimental data to estimate cellular IL-6 interactions in blood.

They characterized IL-6 binding in the IL-6-dependent B9 hybridoma cell line using 125I-labeled rhIL-6 (Fig. 1A). Bioactivity, measured by cell viability, was detectable at a total IL-6 concentration of 0.2 pM and maximized at 2.3 pM (Fig. 1A). Scatchard analysis revealed approximately 164 high-affinity binding sites per cell (Kd ≈ 20 pM) (Fig. 1B).

At the threshold bioactive concentration (0.2 pM total IL-6), cells bound an average of 1.57 molecules, corresponding to just 1% receptor occupancy (Fig. 2A). This minimal binding was sufficient to trigger a measurable proliferative signal. Poisson distribution analysis indicated that at this concentration, 46.5% of cells bound ≥2 IL-6 molecules (Fig. 2B).

At the maximal bioactivity concentration (2.3 pM), cells bound an average of 16.27 molecules. Given that the IL-6 receptor complex functions as a hexamer requiring two IL-6 molecules, these data suggest that activation of merely two receptors (four IL-6 molecules) is sufficient for measurable bioactivity, while activation of approximately eight receptors drives maximal response in vitro.